

Gynecologic Cancer InterGroup (GCIg)

Ovarian Cancer Committee, October 2016, Lisbon

Past-Chair: P.Harter Chair: A.Gonzalez Co-Chair: A Okamoto

Harmonization liaisons: Levin/Pilat (ops); Embleton/Brady (Stats)

Closed Trials Front Line (I)

Surgery and maintenance

- AGO-OVAR OP.3 (LION): Lymphadenectomy in PDS
 - OS analysis ongoing by the end of 2016
- AGO-OVAR 17 / ENGOT OV 15: 15 vs 30 m of bevacizumab in FL
 - PFS analysis Q4 2017
- GOG-212:
 - Maintenance after CR in front line with taxane-carboplatin
 - Paclitaxel x12 vs PG-paclitaxel x12 vs observation
- NOVA /ENGOT OV16 /NSGO
 - Niraparib maintenance after response to platinum in platinum sensitive population
 - Presented By Mirza at ESMO 2016 and published the same day on NEJM


Closed Trials Front Line (II)

Intraperitoneal chemotherapy (IP)

- GOG-252
 - Upfront chemotherapy in optimal and suboptimal disease
 - Carbo IV vs Carbo IP vs CDDP IP
 - Weekly paclitaxel and bevacizumab i 3 arms
 - Presented by Walker et al at SGO 2016.
 - No differences in PFS, neither in OS (immature)
- iPoc trial: GOTIC 001/JGOG3019
 - Carbo IV vs carbo IP (+ weekly paclitaxel both arms)
- NCIC-CTG OV.21
 - Presented by H Mackay at ASCO 2016
 - Carbo IP + Paclitaxel IV/IP after IDS and optimal cytoreduction was well tolerated
 - May be better than IV but study was underpowered to draw definitive conclusions on PFS and OS

Closed Trials Recurrent

- AGO-OVAR OP.4 / DESKTOP III
 - Phase III of cytoreductive surgery in platinum sensitive relapse
 - OS analysis in 2019, planned interim analysis in 2017
- AGO-OVAR 2.21 /ENGOT Ov18
 - Carbo-PLD-bev vs carbo-gem-bev in plat-sensitive relapse
 - Primary PFS in Q1 2018
- SOLO-2
 - Olaparib maintenance in platinum sensitive recurrent BRCA mutated patients who are in CR or PR after platinum based therapy
 - Primary analysis to be presented to SC after Lisbon meeting



Ongoing Trials Front Line

- ICON 8 & ICON 8b
 - ICON 8 closed November 2014
 - PFS on Q1 2017 OS on Q1 2019
- PAOLA-1
- GOG 3005
- PRIMA / ENGOT Ov26 /GEICO 1509
- TRUST /AGO OP.7

Ongoing Trials Recurrent

- INOVATYON
- ENGOT Ov-17/MITO 16b/MANGO Ov2b
- NiCCC
- ENGOT Ov24 / NSGO AVANOVA
- ATALANTE
- GOG-213 (surgery)
- NRG-GY004
- NRG-GY005

New Trials

Updates and new concepts

- AGO-OVAR 2.28 / AGO-OVAR 2.29
- GINECO – OREO (Pujade-Lauraine)
- NCRI – ICON 9 (McNeish)
- NSGO – UMBRELLA (Mirza)
- NCRI – RT in Clear Cell (McCormack)
- NCI US – Phase III in LGSOC with Letrozol (Gershenson)
- GOG – NACT (Bookman)
- SGOG – Targeted Chemotherapy (Chang)
- NCIC-CTG — NEO trial, EVOLVE, STICs and STONES (Oza/Katherine)




GCIG 5th OCCC Tokyo 2015
Status of Publication for
Annals of Oncology

Co-Chairs

K Ochiai, G Stuart, A Okamoto

Processes for Submission



LA; Lead Author
TC; Topic Chair
SC; Scientific Committee member
GD; Group Delegate
CC; Co-chair of 5th OCCC



**Dr Eric Pujade-Lauraine
has kept communication
with Annals of Oncology.**



Update on HRD as predictive factor of response to PARPi

- Mansoor Mirza
- Iain Mcneish
- Discussion